You are here: Industry Insights > ARDS

News List

Altasciences Completes Phase I Study on Gimsilumab for ARDS in COVID-19 americanpharmaceuticalreview
April 01, 2020
Altasciences has completed a Phase I study for the development of gimsilumab, a fully human monoclonal antibody that targets granulocyte-macrophage colony stimulating factor (GM-CSF).
Altasciences Completes Phase I Study in COVID-19 Patients contractpharma
March 30, 2020
Gimsilumab, a monoclonal antibody, is being evaluated in patients with or at risk of developing acute respiratory distress syndrome.
Ampio Preparing Expanded Access FDA Protocol to Study Ampion for Severe COVID-19 ARDS americanpharmaceuticalreview
March 26, 2020
Ampio Pharmaceuticals is preparing an expanded access FDA protocol to study potential benefit of nebulized treatment with Ampion in SARS-Cov-2 (COVID-19) induced Acute Respiratory Distress Syndrome (ARDS).
Roivant Develops Gimsilumab for ARDS Associated with COVID-19 americanpharmaceuticalreview
March 23, 2020
Roivant Sciences has engaged with regulators in the United States, Europe, and Asia to rapidly advance the clinical development of gimsilumab for the treatment ...
Roivant, Mateon to develop Covid-19 drug candidates pharmaceutical-technology
March 20, 2020
Roivant Sciences is in discussion with the US, Europe and Asian regulators to develop gimsilumab for treating acute respiratory distress syndrome (ARDS) caused by Covid-19.
SignPath, Relief explore drugs for Covid-19-related ARDS pharmaceutical-technology
March 19, 2020
SignPath Pharma has begun efforts to develop Lipocurc, an intravenous liposomal curcumin formulation, to treat acute respiratory distress syndrome (ARDS) caused by Covid-19.
MediciNova to Develop Severe Pneumonia, ARDS Treatment americanpharmaceuticalreview
March 11, 2020
MediciNova announced it plans to initiate development of MN-166 (ibudilast) for severe pneumonia and acute respiratory distress syndrome (ARDS).
Faron stock falls on traumakine failure pharmatimes
July 09, 2018
Shares Finnish group Faron Pharmaceuticals were trading down more than 80 percent on the London Stock Exchange after its key drug traumakine failed in acute respiratory distress syndrome (ARDS).

Previous page 1 2 3 4 5 6 7 Next page